Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Apr 27;82(10):1702–1708. doi: 10.1054/bjoc.2000.1207

Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis

H C Kwaan 1, J Wang 1, K Svoboda 1, P J Declerck 2
PMCID: PMC2374508  PMID: 10817507

Abstract

Plasminogen activator inhibitor 1 (PAI-1) has been found to be a bad prognostic factor in a number of tumours but the reason has not been fully explained. The human prostate cancer cell line PC-3 and the human promyelocytic leukaemia cell line HL-60 were used in this study to determine the effect of PAI-1 on spontaneous and induced apoptosis in culture. Apoptosis was induced with camptothecin or etoposide. Addition of a stable variant of PAI-1 or wild-type PAI-1 to these cells resulted in a significant inhibition of apoptosis. In contrast, both the latent form of PAI-1 and the stable variant of PAI-1 inactivated by a specific neutralizing monoclonal antibody, or the stable variant of PAI-1 in a complex with recombinant urokinase did not inhibit apoptosis. This indicated that the inhibitory activity of PAI-1 was required for its anti-apoptotic effect but the urokinase-type plasminogen activator receptor was not involved. These findings provide an explanation for the bad prognostic correlation of high PAI-1 levels in tumours. The anti-apoptotic effect was also found in non-tumoural cells including human umbilical vein endothelial cells and the benign human breast epithelial cell line MCF-10A, suggesting that this is a novel physiologic function of PAI-1. © 2000 Cancer Research Campaign

Keywords: apoptosis, plasminogen activator inhibitor 1, uPA receptor

Full Text

The Full Text of this article is available as a PDF (108.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alizadeh H., Ma D., Berman M., Bellingham D., Comerford S. A., Gething M. J., Sambrook J. F., Niederkorn J. Y. Tissue-type plasminogen activator-induced invasion and metastasis of murine melanomas. Curr Eye Res. 1995 Jun;14(6):449–458. doi: 10.3109/02713689509003755. [DOI] [PubMed] [Google Scholar]
  2. Andreasen P. A., Kjøller L., Christensen L., Duffy M. J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997 Jul 3;72(1):1–22. doi: 10.1002/(sici)1097-0215(19970703)72:1<1::aid-ijc1>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  3. Bajou K., Noël A., Gerard R. D., Masson V., Brunner N., Holst-Hansen C., Skobe M., Fusenig N. E., Carmeliet P., Collen D. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med. 1998 Aug;4(8):923–928. doi: 10.1038/nm0898-923. [DOI] [PubMed] [Google Scholar]
  4. Bashar H., Urano T., Fukuta K., Pietraszek M. H., Hata M., Suzuki K., Kawabe K., Takada Y., Takada A. Plasminogen activators and plasminogen activator inhibitor 1 in urinary tract cancer. Urol Int. 1994;52(1):4–8. doi: 10.1159/000282560. [DOI] [PubMed] [Google Scholar]
  5. Cajot J. F., Bamat J., Bergonzelli G. E., Kruithof E. K., Medcalf R. L., Testuz J., Sordat B. Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. Proc Natl Acad Sci U S A. 1990 Sep;87(18):6939–6943. doi: 10.1073/pnas.87.18.6939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Casslén B., Bossmar T., Lecander I., Astedt B. Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer. Eur J Cancer. 1994;30A(9):1302–1309. doi: 10.1016/0959-8049(94)90178-3. [DOI] [PubMed] [Google Scholar]
  7. Danø K., Andreasen P. A., Grøndahl-Hansen J., Kristensen P., Nielsen L. S., Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139–266. doi: 10.1016/s0065-230x(08)60028-7. [DOI] [PubMed] [Google Scholar]
  8. Debrock S., Declerck P. J. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms. Biochim Biophys Acta. 1997 Feb 8;1337(2):257–266. doi: 10.1016/s0167-4838(96)00173-2. [DOI] [PubMed] [Google Scholar]
  9. Deng G., Curriden S. A., Wang S., Rosenberg S., Loskutoff D. J. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol. 1996 Sep;134(6):1563–1571. doi: 10.1083/jcb.134.6.1563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Egelund R., Schousboe S. L., Sottrup-Jensen L., Rodenburg K. W., Andreasen P. A. Type-1 plasminogen-activator inhibitor -- conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility. Eur J Biochem. 1997 Sep 15;248(3):775–785. doi: 10.1111/j.1432-1033.1997.t01-1-00775.x. [DOI] [PubMed] [Google Scholar]
  11. Foekens J. A., Schmitt M., van Putten W. L., Peters H. A., Kramer M. D., Jänicke F., Klijn J. G. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol. 1994 Aug;12(8):1648–1658. doi: 10.1200/JCO.1994.12.8.1648. [DOI] [PubMed] [Google Scholar]
  12. Gils A., Knockaert I., Declerck P. J. Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop. Biochemistry. 1996 Jun 11;35(23):7474–7481. doi: 10.1021/bi960079d. [DOI] [PubMed] [Google Scholar]
  13. Grøndahl-Hansen J., Christensen I. J., Rosenquist C., Brünner N., Mouridsen H. T., Danø K., Blichert-Toft M. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 1993 Jun 1;53(11):2513–2521. [PubMed] [Google Scholar]
  14. Hofmann R., Lehmer A., Buresch M., Hartung R., Ulm K. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer. 1996 Aug 1;78(3):487–492. doi: 10.1002/(SICI)1097-0142(19960801)78:3<487::AID-CNCR16>3.0.CO;2-V. [DOI] [PubMed] [Google Scholar]
  15. Jänicke F., Schmitt M., Pache L., Ulm K., Harbeck N., Höfler H., Graeff H. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat. 1993;24(3):195–208. doi: 10.1007/BF01833260. [DOI] [PubMed] [Google Scholar]
  16. Kanse S. M., Kost C., Wilhelm O. G., Andreasen P. A., Preissner K. T. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res. 1996 May 1;224(2):344–353. doi: 10.1006/excr.1996.0144. [DOI] [PubMed] [Google Scholar]
  17. Kjøller L., Kanse S. M., Kirkegaard T., Rodenburg K. W., Rønne E., Goodman S. L., Preissner K. T., Ossowski L., Andreasen P. A. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res. 1997 May 1;232(2):420–429. doi: 10.1006/excr.1997.3540. [DOI] [PubMed] [Google Scholar]
  18. Kobayashi H., Fujishiro S., Terao T. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res. 1994 Dec 15;54(24):6539–6548. [PubMed] [Google Scholar]
  19. Kuhn W., Pache L., Schmalfeldt B., Dettmar P., Schmitt M., Jänicke F., Graeff H. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol. 1994 Dec;55(3 Pt 1):401–409. doi: 10.1006/gyno.1994.1313. [DOI] [PubMed] [Google Scholar]
  20. Kwaan H. C. The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev. 1992 Nov;11(3-4):291–311. doi: 10.1007/BF01307184. [DOI] [PubMed] [Google Scholar]
  21. Levenson A. S., Kwaan H. C., Svoboda K. M., Weiss I. M., Sakurai S., Jordan V. C. Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor. Br J Cancer. 1998 Jul;78(1):88–95. doi: 10.1038/bjc.1998.447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Nekarda H., Siewert J. R., Schmitt M., Ulm K. Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer. Lancet. 1994 Jan 8;343(8889):117–117. doi: 10.1016/s0140-6736(94)90845-1. [DOI] [PubMed] [Google Scholar]
  23. Pedersen H., Grøndahl-Hansen J., Francis D., Osterlind K., Hansen H. H., Danø K., Brünner N. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res. 1994 Jan 1;54(1):120–123. [PubMed] [Google Scholar]
  24. Sancho E., Declerck P. J., Price N. C., Kelly S. M., Booth N. A. Conformational studies on plasminogen activator inhibitor (PAI-1) in active, latent, substrate, and cleaved forms. Biochemistry. 1995 Jan 24;34(3):1064–1069. doi: 10.1021/bi00003a042. [DOI] [PubMed] [Google Scholar]
  25. Sier C. F., Vloedgraven H. J., Ganesh S., Griffioen G., Quax P. H., Verheijen J. H., Dooijewaard G., Welvaart K., van de Velde C. J., Lamers C. B. Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. Gastroenterology. 1994 Nov;107(5):1449–1456. doi: 10.1016/0016-5085(94)90549-5. [DOI] [PubMed] [Google Scholar]
  26. Soff G. A., Sanderowitz J., Gately S., Verrusio E., Weiss I., Brem S., Kwaan H. C. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest. 1995 Dec;96(6):2593–2600. doi: 10.1172/JCI118323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Stefansson S., Lawrence D. A. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature. 1996 Oct 3;383(6599):441–443. doi: 10.1038/383441a0. [DOI] [PubMed] [Google Scholar]
  28. Sugiura Y., Ma L., Sun B., Shimada H., Laug W. E., Seeger R. C., DeClerck Y. A. The plasminogen-plasminogen activator (PA) system in neuroblastoma: role of PA inhibitor-1 in metastasis. Cancer Res. 1999 Mar 15;59(6):1327–1336. [PubMed] [Google Scholar]
  29. Verhamme I., Kvassman J. O., Day D., Debrock S., Vleugels N., Declerck P. J., Shore J. D. Accelerated conversion of human plasminogen activator inhibitor-1 to its latent form by antibody binding. J Biol Chem. 1999 Jun 18;274(25):17511–17517. doi: 10.1074/jbc.274.25.17511. [DOI] [PubMed] [Google Scholar]
  30. Waltz D. A., Natkin L. R., Fujita R. M., Wei Y., Chapman H. A. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest. 1997 Jul 1;100(1):58–67. doi: 10.1172/JCI119521. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Wei Y., Waltz D. A., Rao N., Drummond R. J., Rosenberg S., Chapman H. A. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem. 1994 Dec 23;269(51):32380–32388. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES